About AIM Biotech
AIM Biotech is a company based in Singapore (Singapore) founded in 2012. AIM Biotech offers products and services including organiX, idenTx, AngioPrime, and VasQ Kit. AIM Biotech operates in a competitive market with competitors including Pluri, Celloid, S-BIO, The Well Bioscience and ExCel Matrix Biological Devices, among others.
- Headquarter Singapore, Singapore
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aim Biotech Pte. Ltd.
-
Annual Revenue
$4.25 K (USD)0as on Dec 31, 2015
-
Net Profit
-$120.27 K (USD)0as on Dec 31, 2015
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Wavemaker Partners
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AIM Biotech
AIM Biotech offers a comprehensive portfolio of products and services, including organiX, idenTx, AngioPrime, and VasQ Kit.
Enables culture of human tissues for drug discovery research.
Facilitates scalable organ-on-a-chip experiments for testing.
Supports human-relevant models for predictive drug analysis.
Provides tools for vascular biology and drug efficacy studies.
People of AIM Biotech
Unlock access to complete
Unlock access to complete
Funding Insights of AIM Biotech
Investors in AIM Biotech
AIM Biotech has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Wavemaker Partners, SEEDS Capital and Wavemaker 360.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in early-stage technology companies are made by Wavemaker Partners.
|
Locked | Locked | Locked | |
|
Government-backed fund investing in tech startups
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for AIM Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AIM Biotech
Investment portfolio details for AIM Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AIM Biotech
Detailed financials for AIM Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aim Biotech Comparisons
Peer comparison for AIM Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AIM Biotech
AIM Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pluri, Celloid, S-BIO, The Well Bioscience and ExCel Matrix Biological Devices, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Next-generation cell-based products are developed across multiple industries.
|
|
| Locked | Locked | Locked |
3D cell culture solutions for drug development are provided.
|
|
| Locked | Locked | Locked |
Glycan analysis services and kits are offered by S-BIO.
|
|
| Locked | Locked | Locked |
Develops xeno-free hydrogels for 3D cell culture and personalized medicine applications.
|
|
| Locked | Locked | Locked |
Proprietary 3D cell culture technologies are provided for tissue engineering.
|
Detailed competitors of AIM Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aim Biotech
Complete news archive for AIM Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AIM Biotech
AIM Biotech was founded in 2012 and raised its 1st funding round 9 years after it was founded.
AIM Biotech is headquartered in Singapore, Singapore.
Annual revenue of AIM Biotech is $4.25K as on Dec 31, 2015.
A spinout from MIT, AIM Biotech develops and manufactures microfluidic devices for research applications, beginning with 3D cell culture systems. AIMs 3D cell culture chips enable multicellular models to be established in extracellular matrices of the users choice (e.g. collagen, Matrigel, etc.). Stable gradients of pressure or chemicals can be established to model interstitial flow or concentration gradients respectively. Applications developed to date include cell migration, angiogenesis, cancer metastasis (intra-extravasation, spheroid dispersion), chemotaxis and stem cell differentiation. These models can also be used for screening compounds that affect these biological processes. AIM chips are consumables designed to be used with standard cell biology lab equipment without the need for new capital expenditures. AIM Biotech will supply chips accessories to the research community initially, and will expand into the provision of testing services for the pharmaceutical industry. Some key features of AIM microfluidic chips are - Long working regions that are easily injectable with hydrogel, with low risk of leakage; Gas permeable bottom laminate ensures accurate reflections of incubator conditions (normoxic or hypoxic); Multicellular co-culture, with meaningful organization into models of biological systems; Control over chemical gradients and flow across the gel region andor within the media channels. AIM claims its chips provide easy to cast hydrogels for 3D cell culture, and provide excellent optical clarity for various imaging techniques.
AIM Biotech's top competitors include Pluri, Celloid and ExCel Matrix Biological Devices.
AIM Biotech offers organiX, idenTx, AngioPrime, and VasQ Kit.
AIM Biotech has 5 investors. Key investors include Wavemaker Partners, SEEDS Capital, Wavemaker 360, Black Kite Investments, and Elev8.vc.